1997
DOI: 10.1038/sj.bjp.0701445
|View full text |Cite
|
Sign up to set email alerts
|

Antinociceptive activity of CP‐101,606, an NMDA receptor NR2B subunit antagonist

Abstract: 1 The analgesic activity of CP-101,606, an NR2B subunit-selective N-methyl-D-aspartate (NMDA) receptor antagonist, was examined in carrageenan-induced hyperalgesia, capsaicin-and 4b-phorbol-12-myristate-13-acetate (PMA)-induced nociceptive tests in the rat. 2 CP-101,606 30 mg kg 71 , s.c., at 0.5 and 2.5 h after carrageenan challenge suppressed mechanical hyperalgesia without any apparant alternations in motor coordination or behaviour in the rat. 3 CP-101,606 also inhibited capsaicin-and PMA-induced nocicepti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
59
0

Year Published

1999
1999
2015
2015

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 127 publications
(63 citation statements)
references
References 7 publications
4
59
0
Order By: Relevance
“…CHF3381 potently and dose dependently inhibited carrageenan-induced thermal and mechanical hyperalgesia, in agreement with studies indicating a contribution of the NMDA receptor in this model (Ren et al, 1992;Taniguchi et al, 1997). CHF3381 did not modify the physiological responses of the uninjured paw to thermal and mechanical stimuli at the doses tested.…”
Section: Discussionsupporting
confidence: 74%
“…CHF3381 potently and dose dependently inhibited carrageenan-induced thermal and mechanical hyperalgesia, in agreement with studies indicating a contribution of the NMDA receptor in this model (Ren et al, 1992;Taniguchi et al, 1997). CHF3381 did not modify the physiological responses of the uninjured paw to thermal and mechanical stimuli at the doses tested.…”
Section: Discussionsupporting
confidence: 74%
“…Doses of CP-101,606 were selected based on previous studies (Steece-Collier et al, 2000;Taniguchi et al, 1997). In these previous studies, CP-101,606 was effective at reducing haloperidol-induced catalepsy and neuropathic pain in rats over the dose range (2-20 mg/kg) used in the present study.…”
Section: Drug Treatmentmentioning
confidence: 96%
“…Preclinical pharmacological (Taniguchi et al, 1997;Boyce et al, 1999;Suetake-Koga et al, 2006) and genetic (Wei et al, 2001;Tan et al, 2005) studies indicate that GluN2B subunit-containing NMDA receptors may be specifically targeted to treat neuropathic pain (Chizh et al, 2001;Wu and Zhuo, 2009). Prompted by these data, the analgesic efficacy of a single dose of CP-101,606 was tested in a small number of patients suffering from pain due to spinal cord injury and monoradiculopathy, and a clinically meaningful reduction in reported pain was observed (Sang et al, 2003).…”
Section: N-methyl-d-aspartate Antagonistsmentioning
confidence: 99%